Taylor Peak, Yijun Tian, Aman Patel, Tim Shaw, Alyssa Obermayer, Jose Laborde, Youngchul Kim, Joseph Johnson, Paul Stewart, Bin Fang, Jamie K Teer, John Koomen, Anders Berglund, Doug Marchion, Natasha Francis, Paola Ramos Echevarria, Jasreman Dhillon, Noel Clark, Andrew Chang, Wade Sexton, Logan Zemp, Jad Chahoud, Liang Wang, Brandon Manley
A specific splicing isoform of RNASET2 is associated with worse oncologic outcomes in clear cell renal cell carcinoma (ccRCC). However, the interplay between wild type RNASET2 and its splice variant and how this might contribute to the pathogenesis of ccRCC remains poorly understood. We sought to better understand the relationship of RNASET2 in the pathogenesis of ccRCC and the interplay with a pathogenic splicing isoform (RNASET2-SV) and the tumor immune microenvironment. Using data from The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC), we correlated clinical variables to RNASET2 expression and the presence of a specific RNASET2-SV...
February 29, 2024: Laboratory Investigation; a Journal of Technical Methods and Pathology